Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing.

Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing.

BACKGROUND: The purpose of this study was to validate the use of whole-blood samples in the determination of circulating forms of prostate-specific antigen (PSA). METHODS: Blood samples of hospitalized prostate cancer and benign prostatic hyperplasia patients were collected and processed to generate...

Full description

Bibliographic Details
Main Authors:	Piironen, T, Nurmi, M, Irjala, K, Heinonen, O, Lilja, H, Lövgren, T, Pettersson, K
Format:	Journal article
Language:	English
Published:	2001

Similar Items

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
by: Ylikoski, A, et al.
Published: (2002)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
by: Siivola, P, et al.
Published: (2000)

Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step.
by: Niemelä, P, et al.
Published: (2002)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
by: Becker, C, et al.
Published: (2000)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
by: Ylikoski, A, et al.
Published: (2001)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
by: Nurmikko, P, et al.
Published: (2001)

Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).
by: Peltola, M, et al.
Published: (2011)

Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA.
by: Nurmikko, P, et al.
Published: (2000)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
by: Väisänen, V, et al.
Published: (2006)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
by: Becker, C, et al.
Published: (2000)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Biology of prostate-specific antigen
by: Lilja, H
Published: (2003)

Biology of prostate-specific antigen.
by: Lilja, H
Published: (2003)

Acoustic whole blood plasmapheresis chip for prostate specific antigen microarray diagnostics.
by: Lenshof, A, et al.
Published: (2009)

Acoustic whole blood plasmapheresis chip for prostate specific antigen microarray diagnostics.
by: Lenshof, A, et al.
Published: (2009)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
by: Wenske, S, et al.
Published: (2009)

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
by: Steuber, T, et al.
Published: (2002)

The Effects of Topical Ketamine in Reducing Venipuncture Pain
by: Farhad Heydari, et al.
Published: (2019-10-01)

Circulating biomarkers for prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
by: Cao, Y, et al.
Published: (2002)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
by: Steuber, T, et al.
Published: (2005)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
by: Ulmert, D, et al.
Published: (2006)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
by: Becker, C, et al.
Published: (2000)

Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
by: Piironen, T, et al.
Published: (2006)

Biopsychosocial Contributors to Parent Behaviors during Child Venipuncture
by: Kaytlin L. Constantin, et al.
Published: (2022-07-01)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
by: Botchorishvili, G, et al.
Published: (2009)

[Isoforms of free prostate-specific antigen]
by: Haese, A, et al.
Published: (2004)

Isoforms of free prostate-specific antigen
by: Haese, A, et al.
Published: (2004)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
by: Haese, A, et al.
Published: (2001)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
by: Haese, A, et al.
Published: (2004)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Can the use of infrared vein finder help refine venipuncture?
by: Noman Mansoor, et al.
Published: (2023-09-01)

Vacuum-venipuncture skills: time required and importance of tube order
by: Fujii C
Published: (2013-08-01)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
by: Becker, C, et al.
Published: (2001)

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
by: Ulmert, D, et al.
Published: (2012)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
by: Vickers, A, et al.
Published: (2009)